Please assess the completion status of the following clinical trial:

Trial Title: Dolutegravir Interactions With Artemisinin-based Combination Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.~2. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~3. Men and women aged 18 years and above~4. Weight ≥40 kg~5. HIV antibody negative at screening.~6. Malaria blood film negative at screening~7. Willing to use mosquito bednets routinely for the duration of the study~8. Women of childbearing potential must be willing to use an effective barrier contraception method for the duration of the study.~Exclusion Criteria:~1. Significant disease affecting cardiac, respiratory, gastrointestinal or neurological symptoms which in the clinician's medical judgment could be worsened by participating in this study or the presence of medical or surgical conditions which could prevent the subject from complying with study procedures.~2. Serum alanine transaminase (ALT) levels above 3x upper limit of normal~3. Serum creatinine levels above 2x upper limit of normal~4. Hepatitis B surface antigen positive~5. Use of medications which are known inducers/inhibitors of CYP or glucuronyl transferase UGT1A1 within past 2 months (e.g. anticonvulsants, TB medications, HIV agents for prophylaxis, azole antifungals)~6. Evidence of QT prolongation on electrocardiogram (ECG) QTc (Rate adjusted QT interval) \>450ms (men) or \>470ms (women)~7. Pregnant women or female subjects who are unwilling to use a suitable contraceptive method for the duration of the study (condom, diaphragm, IUD or contraceptive implant)~8. Likely to be poorly adherent based on clinician's medical judgement~9. Known to be current injection drug user

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Study A Sequence 1 (Type: EXPERIMENTAL): Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
- Study A Sequence 2 (Type: EXPERIMENTAL): Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
- Study B Sequence 1 (Type: EXPERIMENTAL): Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
- Study B Sequence 2 (Type: EXPERIMENTAL): Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state

Based on this trial design, predict the completion outcome and termination type (if applicable).